About Catapharma
Catapharma is a Healthcare company based in Nashik (India) founded in 1986 by Shrikant Karwa. It produces high-quality bulk drugs and intermediates with expertise in liquid-phase hydrogenation. It operates on a B2B model. Its Indian entity Catapharma (India) Pvt Ltd reported revenue of ₹3.60 Cr. Its focus areas include Pharmaceuticals, Drug Manufacturing and Bulk Drugs and Intermediates. Similar companies include Laurus Labs, Symbiotec and SeQuent; 2 of its 3 listed similar companies have raised funding.
Company details
Catapharma, based in Nashik, focuses on providing healthcare solutions, producing pharmaceutical products, drug manufacturing, and bulk drugs and intermediates. Produces high-quality bulk drugs and intermediates with expertise in liquid-phase hydrogenation. The company prioritizes operational excellence, innovation, and customer-centric approaches for success.
- Headquarters Nashik, India
- Founders Shrikant Karwa
- SectorsHealthcare
- Email••••••••
- Website catapharma.com
- Legal Name Catapharma (India) Pvt Ltd
- Date of Incorporation 29 Oct, 1986
- Jurisdiction Nashik, Maharashtra, India
- Annual Revenue₹3.60 Cr
FY 2025 · -83% YoY
- Net Profit₹68.5 Lakh
FY 2025 · 19% margin
- EBITDA₹80.9 Lakh
FY 2025 · 23% margin
Associated legal entities of Catapharma
Catapharma is associated with 2 registered companies on The Company Check; the primary company is Catapharma (India) Pvt Ltd. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Catapharma (India) Pvt Ltd CIN U99999MH1986PTC041424 | Active | 29 Oct 1986 | Nashik, Maharashtra | ₹3.6 Cr | 2 | View details | |
| Mdb Chemicals (India) Private Limited CIN U24110MH1998PTC118719 | Active | 08 Dec 1998 | Nashik, Maharashtra | ₹90.4 Cr | 31 | 2 | View details |
Board of directors of Catapharma (India) Pvt Ltd (Catapharma)
Catapharma (India) Pvt Ltd is the primary company behind Catapharma. The boards of the 2 registered companies of Catapharma currently have 3 directors; the longest-serving is Shrikant Laxminarayan Karwa, appointed in 1986. 1 earlier director has ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Shrikant Laxminarayan Karwa DIN 00033809 | Managing Director | 29 Oct 1986 | 39 yrs 11 mo | Catapharma (India) Pvt Ltd, Mdb Chemicals (India) Private Limited |
| Pankaj Murlidhar Kabra DIN 00033927 | Director | 08 Dec 1998 | 27 yrs 10 mo | Mdb Chemicals (India) Private Limited |
| Manju Shrikant Karwa DIN 09065487 | Director | 18 Feb 2021 | 5 yrs 8 mo | Catapharma (India) Pvt Ltd |
People of Catapharma
1 people are tracked at Catapharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Founder | Leadership |
Complete people profiles for Catapharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of Catapharma
Figures of Catapharma (India) Pvt Ltd, the primary company behind Catapharma, for FY 2025. Revenue was ₹3.60 Cr (-83% year on year). Net profit was ₹68.5 Lakh (19% margin). EBITDA was ₹80.9 Lakh (23% margin). Revenue has grown at a compounded annual rate of -37% over three years and +52% over five years.
- ₹3.60 CrRevenue · FY 2025 · -83% YoY
- ₹68.5 LakhNet profit · 19% margin
- ₹80.9 LakhEBITDA · 23% margin
- ₹8.5 LakhPaid-up capital
- -37%Revenue CAGR, 3 years
- +52%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Catapharma (India) Pvt Ltd are on its company page.
Detailed financial statements for Catapharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Catapharma
Catapharma has 3 listed similar companies in our database, 2 of them funded. They include Laurus Labs, Symbiotec and SeQuent.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lauruslabs.com | 2005 | Hyderabad, India | $229.73M | 6,035 | Pharmaceutical and biotechnology company | |
| symbiotec.in | 2002 | Indore, India | $61.01M | 1,822 | Non-sterile steroid hormone-based APIs and intermediates are manufactured. | |
| sequent.in | 2002 | Bengaluru, India | APIs are developed and manufactured for therapeutic areas. |
Detailed similar companies of Catapharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Catapharma
The website of Catapharma (catapharma.com) receives about 1.2K visits a month.
- Monthly visits1.2K
▲ 4.3% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Catapharma
Catapharma was founded in 1986.
Catapharma is headquartered in Nashik, India. It is registered at Nashik, Maharashtra, India.
The primary company behind Catapharma, Catapharma (India) Pvt Ltd, reported revenue of ₹3.60 Cr for FY 2025, down 83% year on year.
Catapharma, based in Nashik, focuses on providing healthcare solutions, producing pharmaceutical products, drug manufacturing, and bulk drugs and intermediates. Produces high-quality bulk drugs and intermediates with expertise in liquid-phase hydrogenation. The company prioritizes operational excellence, innovation, and customer-centric approaches for success.
Catapharma's top competitors include Laurus Labs, Symbiotec and SeQuent.
Catapharma is associated with 2 legal entities: Catapharma (India) Pvt Ltd, Mdb Chemicals (India) Private Limited.
The legal entities of Catapharma currently have 3 directors, including Manju Shrikant Karwa, Shrikant Laxminarayan Karwa, Pankaj Murlidhar Kabra.